Enable JavaScript to visit this website.

Utility Menu

Results you can see

The EUCRISA clinical trial program included more than 1500 people with mild-to-moderate eczema, ages 2 to 79, with over 1000 people receiving EUCRISA. Of those, the majority were kids ages 2 to 17. In clinical trials, more people using EUCRISA (32%) achieved clear or almost clear skin than people using the non-medicated Emollient-Rich Vehicle (22%) after 28 days. Some saw clear to almost clear skin in about a week.

VIEW PHOTOS IN OUR GALLERY BELOW TO SEE RESULTS FROM CLINICAL TRIALS AND REAL-WORLD PATIENTS

Slider Image Alt
loading symbol
loading symbol
Body description

Body part result

Explore the different images to see how EUCRISA worked over time to treat
mild-to-moderate eczema.
real photo of eczema on forearm
real photo of eczema on forearm 1
Forearm
real photo of eczema on left hand
real photo of eczema on left hand 1
Hand
real photo of eczema on chin
real photo of eczema on chin 1
Chin
real photo of eczema on thumb
real photo of eczema on thumb 1
Thumb
real photo of eczema on wrist
real photo of eczema on wrist 1
Wrist
For topical use only. Do not use in eyes, mouth, or vagina.
calendar

STICK WITH YOUR TREATMENT PLAN

Some people using EUCRISA saw results in as little as 8 days, while even more people were clear or almost clear after 28 days. You should continue to use EUCRISA as prescribed by your doctor.

Some patients may experience burning or stinging where EUCRISA is applied. In our clinical trials, 4% of EUCRISA and 1% of vehicle-treated patients experienced this side effect, and application site pain resolved within 1 day for 78% of those patients.

WHAT IS THE MOST IMPORTANT SAFETY INFORMATION I SHOULD KNOW ABOUT EUCRISA?

EUCRISA may cause side effects including allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.

In clinical trials, 4% of EUCRISA patients experienced application site pain, such as burning or stinging, vs 1% of those who used the non-medicated vehicle. A long-term safety trial (48 weeks) showed a 2% incidence of application site pain in those treated with EUCRISA.

man and woman sitting at a table with resolved eczemaman and woman sitting at a table with resolved eczema 1man and woman sitting at a table with resolved eczema 2

Want to share your
EUCRISA
story with us?

We'd love to hear from you.

Eucrisa for you

Request the EUCRISA
Copay
Savings Card and
see how
eucrisa•4•you
may help!

Eligibility required. Savings up
to $970 per tube.
Annual savings
up to $3,880. State and federal

beneficiaries not eligible.
Terms and conditions apply.

Important Safety Information & Indication
 

IMPORTANT SAFETY INFORMATION

Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.

EUCRISA may cause side effects including allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.

The most common side effect of EUCRISA is application site pain, such as burning or stinging.

EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth, or vagina.

INDICATION
EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and children 2 years of age and older.

See Full Prescribing Information .

Exit Link PopUp

You are now leaving EUCRISA.com
Links to external websites are provided as a convenience to the viewer. Pfizer accepts no responsibility for the content of linked sites.
Continue
Stay on this site >
TERMS AND CONDITIONS

EUCRISA® (crisaborole) ointment, 2%
Copay Savings Card

By using the EUCRISA Copay Savings Card (the "Card"), you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions.

  • Patients are not eligible to use this card if they are enrolled in a state or federally funded prescription insurance program, including Medicare Part D, Medicaid, TRICARE, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). If you are enrolled in a state or federally funded prescription insurance program, you may not use this savings card even if you elect to be processed as an uninsured (cash-paying) patient.
  • This Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your commercial insurance plan or any other health or pharmacy benefit program.
  • By using this Card at participating pharmacies, eligible patients with commercial prescription drug insurance coverage for EUCRISA may pay as little as $10 per tube. Eligible patients with commercial prescription drug insurance coverage that does not cover EUCRISA may pay as little as $70 per tube. Eligible patients without prescription drug insurance who pay cash may pay as little as $100 per tube. Individual savings are limited to $970 per tube. Individual patient savings are limited to $3,880 in maximum total savings per calendar year.
  • You must deduct the value of the savings that you receive from this Card from any reimbursement request submitted to your commercial insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting receipt of any savings from the Card to any commercial insurer, health plan, or other third party that pays for or reimburses any part of the cost of the prescription filled using the Card, as may be required by such insurer or plan. You should not use the Card if your insurer or health plan prohibits use of manufacturer copay cards.
  • This copay program is not valid where prohibited by law.
  • The Card cannot be combined with any other rebate/copay program, free trial or similar offer for the specified prescription.
  • The Card will be accepted only at participating pharmacies.
  • This Card is not health insurance.
  • Offer good only in the U.S. and Puerto Rico.
  • The Card is limited to 1 per person during this offer period and is not transferable.
  • The Card may not be redeemed more than once per 30 days per patient.
  • No other purchase is necessary.
  • Data related to your redemption of the Card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this offer at any time without notice.
  • No membership fees.
  • Offer expires 03/31/20.

If you have questions or are in need of additional support, call 1-877-548-1739. Pfizer Inc, PO Box 29387, Mission, KS 66201.

Important Safety Information & Indication
 

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION AND INDICATION

Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.

EUCRISA may cause side effects including allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.

The most common side effect of EUCRISA is application site pain, such as burning or stinging.

EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth, or vagina.

INDICATIONEUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and children 2 years of age and older.

See Full Prescribing Information and Patient Information.

For more information call 1-866-EUCRISA (1-866-382-7472)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

Copyright © 2019 Pfizer Inc.
All rights reserved.

Pfizer, PO Box 29387, Mission, KS 66201

Last Updated: July 2019
PP-CRI-USA-1238

Pfizer logo
Important Safety Information & Indication
 

IMPORTANT SAFETY INFORMATION

Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.

EUCRISA may cause side effects including allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.

The most common side effect of EUCRISA is application site pain, such as burning or stinging.

EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth, or vagina.

INDICATION
EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and children 2 years of age and older.

See Full Prescribing Information .